Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

pharmafile | April 4, 2016 | News story | Research and Development, Sales and Marketing |  Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent 

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure patients, in those that were considered clinically stable just as much as it did those who were least-stable.

Results from the trial show that Entresto is just as useful in patients considered stable, as even those patients were identified as at risk of a serious clinical event. In the analysis, over one third of patients were identified as clinically stable, and 20% of those experienced a primary endpoint event (cardiovascular death or heart failure hospitalisation).

The data suggests that Entresto benefitted patients across the board with patients taking the drug having a 20% or greater reduction in cardiovascular death or heart failure hospitalisation compared to those taking enalapril. It showed consistent benefits in reducing the risk of these adverse events, regardless of background therapy.

Vas Narasimhan, global head of drug development and chief medical officer, comments: “This new analysis shows that heart failure patients are never truly stable since in the majority of patients their first clinical event was death. We cannot afford to wait for patients to worsen to use Entresto and improve their chance at a better length of life.”

Entresto was characterised as being of an “innovative nature” in a recent approval granted by NICE.

Sean Murray